The FTSE 100 pharmaceuticals firm, AstraZeneca, has won Europe-wide approval for its diabetes drug Komboglyze.
The treatment, which was developed in conjunction with US peer Bristol-Myers Squibb, helps glycaemic control in adult patients with type 2 diabetes.
The approval comes following a study involving 4,326 patients.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. In Europe alone there are around 50 million people suffering with the condition.
The share price fell marginally by 0.04% to 2,820p by 08:20.
MoneyWeek Interviews: Ed Wielechowski portfolio manager of the Odyssean Investment Trust
Ed Wielechowski portfolio manager of the Odyssean Investment Trust talks to Rupert Hargreaves.
By Rupert Hargreaves Published
Pension savers turn to gold investments
Investors are racing to buy gold to protect their pensions from a stock market correction and high inflation, experts say
By Ruth Emery Published